Redeye revises its Base Case and estimates following an analyst change, retaining its positive view. While Q4 face tough comparable numbers, with Vitec trading at the lowest EV/Sales NTM since 2020, we believe the market is too pessimistic about the long-term prospects.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.www.redeye.se/
Attachments